B
BioShin
Develop and sell a series of Biohaven pharmaceutical products in Asia
About BioShin
BioShin is a Shanghai-based biopharmaceutical company operating as an Asia-Pacific subsidiary of the U.S. firm Biohaven Pharmaceutical Holding Company Ltd. Established in 2018, BioShin's primary objective is to develop and commercialize Biohaven's late-stage clinical portfolio for patients in the Asia-Pacific region, excluding Japan. The company focuses on addressing the significant unmet medical needs in neurologic and neuropsychiatric diseases, such as migraine, which affects an estimated 90 million individuals in China alone.
The formation of BioShin was a strategic move by Biohaven to tap into the burgeoning Asia-Pacific healthcare market, driven by regulatory changes and a growing patient population. Initially led by Donnie McGrath, M.D., who transitioned from his role at Biohaven, the company appointed Karl Lintel as CEO in September 2020. Lintel brought extensive experience from his previous roles as President and General Manager of Bristol-Myers Squibb in China. The broader management team comprises veterans from major pharmaceutical companies like Pfizer, Sanofi, and Novartis, highlighting a deep well of international and regional expertise.
BioShin's business model centers on licensing and advancing Biohaven's drug pipeline. The company secured a significant milestone in September 2020 by closing a $60 million Series A funding round led by OrbiMed, with participation from other notable healthcare investors. This capital infusion was earmarked to fund the build-out of its operations in China and to advance clinical trials for key product candidates. The company's core activity is conducting clinical trials to gain regulatory approval for these drugs in markets like China and South Korea. A primary product in its portfolio is rimegepant (marketed as Nurtec ODT in the U.S.), an orally administered treatment for acute migraine. BioShin has been conducting a Phase 3 trial for rimegepant in China and South Korea. The company is also advancing trials for troriluzole, a treatment for the rare genetic movement disorder Spinocerebellar Ataxia (SCA).
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 22.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Sep 2020 | $60M | $240M | Suvretta Capital Management · Citadel · Cormorant Asset Management · OrbiMed | — |
Growth signals
Latest recorded traffic for BioShin is 50 monthly website visits, down 70.6% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
BioShin in the Pudong ecosystem
The BioShin office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
OrbiMed
Suvretta Capital Management
Citadel
Cormorant Asset Management
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioShin on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioShin’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









